

# Index

## A

Abdominal mass, 6  
Actin cytoskeleton reorganization, 29  
Adherens junctions, 27  
Adjuvant chemotherapy, 7  
Alcohol, 20, 113  
Anti-angiogenesis drugs, 8  
Anti-epidermal growth factor drugs, 8  
Apicobasal polarity, 26  
Apoptotic bodies, 58

## B

Barrett's esophagus, 112  
Bevacizumab, 8  
Biomarker assay development, 89  
Biomarkers, 73, 85

## C

CA19–9, 7, 91  
Calcium, 17  
CAPEOX, 8  
Carbohydrate antigen, 19–9, 7  
Carcinoembryonic antigen, 7  
Carney triad syndrome, 45  
Carney–Stratakis syndrome, 45  
Cell polarity loss, 27  
Cell-cell adhesion disruption, 27  
Cellular alterations, 26  
Cervical anastomosis technique, 119  
Cervicotomy incision, 119  
Cetuximab, 8

Chemoresistance, 35  
Chemotherapy, 7  
Circulating tumor cells, 29  
Clinical manifestations, 6  
Clinical presentation, 45  
Clinical validation, 92  
Clinicopathological features, 43  
Coffee and other caffeine sources, 20  
Colorectal cancer, 1, 13, 68  
Commercial test model, 92  
Computed tomography, 7

## D

Dairy products, 17  
Diagnosis, 6, 45, 113  
Diagnostic tools, 88  
Diet, 13  
Dietary factors, 4  
Dietary fiber, 16

## E

Early detection, 85  
Early esophageal carcinoma, 114  
Early pancreatic neoplasia, 87  
E-cadherins, 27  
Endoscopy, 7  
Epidemiology, 3, 101  
Epithelial-mesenchymal transition, 25  
Esophageal cancer, 111  
Esophagectomy without thoracotomy, 116  
Esophagectomy, 111

Etiology, 4, 15  
Exosomes, 58  
Extracellular vesicles, 57  
Extraluminal portion, 52

## F

Familial GIST, 45  
Fecal occult blood test, 7  
Folate, 18  
FOLFIRI, 8  
FOLFOX, 8  
FOLFOXIRI, 8

## G

Garlic, 19  
Gastric cancer, 58, 78  
Gastric GIST, 52  
Gastroesophageal reflux disease, 112  
Gastrointestinal cancers, 57, 73  
Gastrointestinal stromal tumors, 43  
Gender and race, 112  
Genetic abnormalities, 5  
Genetic alterations, 30  
Genetic factors, 4, 113  
Genetic implications, 112  
GERD, 112  
GIST, 43  
Glycosylation reactions, 33

## H

*Helicobacter pylori*, 102  
Hematochezia, 6  
Hematogenous metastasis, 6  
Hepatocellular carcinoma, 67  
Histological changes, 5  
Hyperinsulinemia, 15

## I

Identifying individuals at high risk, 87  
Immunohistochemistry, 46  
Immunoregulatory proteins, 90  
Immunotherapy, 8  
Implantation and metastasis, 6  
Incidence 13, 103  
Interstitial cells of Cajal, 44  
Intestinal obstruction, 6  
Intragastric resection, 50  
Ivor Lewis esophagectomy, 116

## J

Japanese classification, 2  
Junctional adhesion molecules, 27  
Junctional complex, 27

## K

KIT, 44  
KLF-3, 60  
K-ras, 5, 18  
Kupfer cells, 66

## L

Laparoscopic gastric wedge resection, 50  
Laparoscopic step, 118  
Laparoscopic gastrectomy, 51  
Large intestine, 2  
Lifestyle, 13  
Local invasion, 6  
Lymphatic metastasis, 6

## M

Macrophage, 57  
Magnesium, 19

McKeown esophagectomy, 116, 117  
Mesenchymal tumors, 44  
Mesenchymal-epithelial transition, 26  
Metastasis, 5  
Metastatic colorectal cancer, 25  
Microparticles, 58  
microRNA, 59  
Minimally invasive  
    esophagectomy, 111, 116, 117  
Mortality rates, 104  
Multigene expression biomarkers, 73

## N

Neoadjuvant chemotherapy, 7  
Neoadjuvant treatment, 115  
Non-cancerous diseases, 4  
Nuclear magnetic resonance, 7

## O

Obesity, 15, 113  
Oncotype DX colon cancer test, 75  
Open vs laparoscopic surgery, 53  
Optimization study, 91  
Outcomes, 117

## P

Palliative care, 8  
Palliative chemotherapy, 7  
Pan-cancer biomarker assays, 97  
Pancreatic cancer, 64  
Pancreatic ductal adenocarcinoma, 85  
Pathogenesis, 4  
Pathological type, 5  
Pathology, 46  
PDGFRA, 44  
Pescatarian diet, 16

Physical activity, 14  
Planar cell polarity, 27  
Platelet-derived growth factor  
    receptor-alpha, 44  
Polyps, 4, 14  
Positron emission computed tomography, 7  
Post-translational modifications, 31  
Precursor lesions, 87  
Predicting therapeutic benefit, 73  
Prevention, 8  
Prognosis, 8  
Prognostic factors, 48  
Prognostic performance, 79  
Prognostic scoring system, 78  
Prognostic signatures, 79  
Protein microarray technology, 89

## Q

Quality of life, 8

## R

Radical surgery, 7  
Radioresistance, 34  
Radiotherapy, 8  
Red and processed meat, 15  
Risk classification, 48  
Risk factors, 112

## S

Sample cohort characteristics, 93  
Screening methods, 5  
Single port under laparoscopic control, 50  
Smoking, 112  
Stage I esophageal carcinoma, 115  
Staging, 47  
Stomach cancer, 101

Submucosal tumor, 49  
Surgical management, 43  
Surgical techniques, 49  
Surgical treatment, 116  
Survival, 13  
Systemic symptoms, 6

## T

Therapeutic strategies, 113  
Therapy resistance, 32  
Thoracoscopic step, 118  
Tight junctions, 27  
TNM classification, 114  
Tobacco, 20  
Transcription factors, 30  
Treatment, 7, 47  
Tumor markers, 7  
Tumor-derived biomarker, 91  
Type-1 neurofibromatosis, 45  
Tyrosine kinase inhibitors, 45

## U

Ubiquitylation, 29  
Ulcerative colitis, 4  
Ultrasonography, 7

## V

Vimentin, 29  
Vitamin B6, 19  
Vitamin D, 17

## W

Weight loss, 7  
White meat, 16  
Wnt, 26  
Wnt/ $\beta$ -catenin, 29

## X

XIAP, 65  
X-ray, 7

## Y

YOD1/YAP/ $\beta$ -catenin, 61  
Young patients, 44

## Z

Zeb, 26, 31  
Zinc finger, 30  
Zonula occludens proteins, 27

DOI: <https://doi.org/10.36255/exon-publications-gastrointestinal-cancers.index>